Skip to content

Streetlab and Iris Pharma: a partnership to integrate quality of life into the clinical evaluation of new products for the visually impaired

  • by

Paris, February 1, 2017 – Streetlab, a company working to improve the autonomy, mobility and quality of life of visually impaired people announces the signing of a strategic partnership agreement with Iris Pharma, a contract research company specialized in the development of drugs and medical devices in the field of ophthalmology. This partnership is the basis of a new service offering for the pharmaceutical industry with the integration of a human factors oriented methodological approach in the evaluation of new drugs, medical devices or technologies for the visually impaired.

Streetlab has several innovative experimentation platforms in Paris, within the Institut de la Vision, which are real solutions for evaluating the mobility strategy, the gaze and the apprehension of objects of visually impaired people through movement capture systems in controlled and reproducible environmental conditions. Within the framework of this partnership, Iris Pharma brings its nearly 30 years of experience in ophthalmology as well as its unique expertise and knowledge of all phases of research and development, particularly in the set-up and management of clinical trials. “We are delighted with this partnership which will bring us synergy in the management of clinical trials. The therapeutic benefit of post-drug or post-surgical treatment is now objectively measurable by means of an innovative evaluation of their impact on the realization of tasks of daily life” explains Mr. Emmanuel Gutman, Managing Director of Streetlab.

As demographic trends in industrialized countries lead to a significant increase in the number of visually impaired people, the acceleration of scientific progress in ophthalmology heralds important therapeutic innovations to come. “By combining our respective fields of expertise, we will together provide healthcare companies with evaluation criteria for clinical trials that are calibrated, innovative and adapted as closely as possible to the specific needs of visually impaired patients, and thus provide the best possible response to the challenges of innovation,” explains Yann Quentric, President of Iris Pharma.

About Streetlab

Created by the Institut de la Vision at the initiative of Professor José-Alain Sahel, Streetlab’s objective is to evaluate products and services to improve the autonomy, mobility and quality of life of visually impaired people. Through its close collaboration with the Quinze-Vingts Hospital, the company benefits from a first class medical and scientific expertise.

About Iris Pharma

Iris Pharma is an independent contract research organization specialized in preclinical and clinical research in the field of ophthalmology. Founded in 1989 by Pierre-Paul Elena and now headed by Yann Quentric, Iris Pharma offers expertise in the development of ophthalmic drugs and ocular medical devices to pharmaceutical and biotechnology companies worldwide. Iris Pharma’s services include preclinical studies and services (GLP and non-GLP safety and pharmacokinetic studies, efficacy studies), clinical trials (phase I to IV and medico-marketing surveys), bioanalysis, preclinical formulation, and strategic consulting. Iris Pharma’s research laboratories are GLP compliant.


Iris Pharma – Yann Quentric

StreetLab – Emmanuel Gutman

For press – Katia Barcaroli